Connected drug delivery devices market to grow to $4bn by 2028
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
List view / Grid view
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
Collaboration also includes strategic investment by Aptar Pharma; will add connectivity to drug-delivery routes to improve adherence and treatment outcomes...